Friday, July 10, 2026

Drug profile · INN

tesamorelin

tesamorelin (EGRIFTA) is a growth hormone-releasing hormone receptor agonist.

EMA: application withdrawn NMPA: clinical trials
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — tesamorelin
Class
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

tesamorelin (EGRIFTA) is a growth hormone-releasing hormone receptor agonist.

Key facts

INN tesamorelin
Brand EGRIFTA
Mechanism Growth hormone-releasing hormone receptor agonist

Mechanism of action

Growth hormone-releasing hormone receptor agonist

Approval history

Authority Status Date
EMA application withdrawn
NMPA clinical trials

Pipeline programs

  1. Tesamorelin 2 Milligrams (MG) Phase 2 · United Therapeutics Europe · Peripheral Nerve Injuries

Frequently asked questions

What is tesamorelin?

tesamorelin (EGRIFTA) is a growth hormone-releasing hormone receptor agonist.

What is the brand name for tesamorelin?

EGRIFTA is a marketed brand name for tesamorelin. Check FDA Drugs@FDA for the current US label holder and prescribing information.